Toujeo is an injectable insulin medication for the treatment of diabetes (type 1 or type 2) in people who are 6 years old and older. It is a long-acting form of insulin, which allows it to last for a ...

Toujeo (insulin glargine) is a prescription brand-name medication. It’s approved by the Food and Drug Administration (FDA) to treat type 1 or type 2 diabetes. The drug is for use in adults as well as ...

Toujeo is a long-acting form of insulin. It works by lowering the level of blood sugar in the body. It is not used for diabetic ketoacidosis. Toujeo is given as a subcutaneous injection. For ...

Sanofi said it has found adults with type 2 diabetes treated with its Toujeo® insulin injection experienced a consistently lower rate of confirmed or severe hypoglycemia both at night and at any time ...

* CHMP adopts positive opinion for expanded indication for Toujeo in children and adolescents (aged 6 to 17 years) with diabetes The trial, EDITION JUNIOR, is the first randomized, controlled trial ...

The European Union has given the nod to a new formulation of insulin glargine (Toujeo, Sanofi), which is a higher-strength insulin (300 units/mL) than the existing insulin glargine product on the ...

The FINANCIAL — Sanofi announced on February 26 that the U.S. Food and Drug Administration (FDA) approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal ...

PARIS (Reuters) - French drugmaker Sanofi plans to launch its new Toujeo insulin for diabetics in the United States on Monday, according to a source familiar with the matter. Toujeo was approved for ...

The FDA has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged ≥6 years with diabetes mellitus. The Food and Drug Administration ...

The FINANCIAL — Sanofi announced on April 28 that the European Commission has granted marketing authorization in Europe for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a ...

Sanofi-Aventis Korea, the local affiliate of France-based global health care company Sanofi, presented the benefits of its newly upgraded basal insulin Toujeo in an event in Seoul on Monday to ...